The AHA today commented on the Food and Drug Administration’s draft guidance for industry and FDA staff on clinical decision support software as part of the agency’s efforts to implement Section 3060(a) of the 21st Century Cures Act. AHA expressed concern that “FDA’s interpretation of certain criteria could result in many existing CDS algorithms being subject to the FDA approval process and ultimately slow the pace of innovation and development of new algorithms to support better patient care and outcomes.” In its letter, AHA shared specific recommendations with FDA and said it “looks forward to working with the FDA to ensure the agency’s regulatory approach to implementing Section 3060(a) is consistent with the language and intent of the Cures Act and prioritizes patient safety while at the same time allowing hospitals and health systems to continue to implement innovative decision support tools.”

Related News Articles

Headline
Randy Fagin, M.D., chief quality officer at HCA Healthcare, shares how one of the nation’s largest health systems is putting artificial intelligence into…
Headline
The National Institutes of Health Aug. 5 issued guidance to researchers on the use of artificial intelligence for the research application process. According…
Headline
The AHA Aug. 7 filed an amicus brief in the Supreme Court in defense of states’ affidavit of merit requirements in federal court, which require plaintiffs to…
Headline
The American Society for Health Care Engineering July 28 announced the recipients of its annual member awards during the 2025 Health Care Facilities Innovation…
Headline
The American Society for Health Care Engineering July 1 announced 87 health care facilities as winners of the 2025 Energy to Care Sustainability Champions…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…